Canopy Growth (CGC) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Canopy Growth (CGC) over the past year, gaining 25.6% versus a loss of 44.7%. Over five years, EOLS leads with a +1.7% price change compared with -99.4% for CGC. Evolus is the larger company by market cap ($509.2 million vs $370.4 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | EOLS |
|---|---|---|
| Share price | $0.8243 | $7.71 |
| Market cap | $370.36M | $509.25M |
| 1-day change | -2.66% | -1.15% |
| YTD return | -25.72% | +17.29% |
| 1-year return | -44.65% | +25.60% |
| 5-year return | -99.37% | +1.69% |
| Forward P/E | — | 26.36 |
| EPS (TTM) | $-0.45 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $9.31 |
| 52-week low | $0.81 | $3.86 |
| Distance from 52-week high | -65.37% | -17.19% |
| Analyst consensus | none | none |
| Avg. price target upside | +45.58% | +94.55% |
| Average volume | 2.77M | 900.79K |
| Shares outstanding | 423.04M | 66.05M |
| Employees | 1,128 | 353 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed CGC by 70.3 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
CGC vs EOLS FAQ
Which is bigger, Canopy Growth or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $509.25M compared with $370.36M for Canopy Growth (CGC).
Which stock has performed better over the past year, CGC or EOLS?
EOLS returned +25.60% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Evolus in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Canopy Growth and Biotechnology: Pharmaceutical Preparations for Evolus.